UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000028298
Receipt No. R000032260
Scientific Title Single-arm confirmatory trial of endocrine therapy alone for estrogen receptor-positive, low-risk ductal carcinoma in situ of the breast (JCOG1505, LORETTA trial)
Date of disclosure of the study information 2017/07/20
Last modified on 2017/07/20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Single-arm confirmatory trial of endocrine therapy alone for estrogen receptor-positive, low-risk ductal carcinoma in situ of the breast (JCOG1505, LORETTA trial)
Acronym Single-arm confirmatory trial of endocrine therapy alone for estrogen receptor-positive, low-risk ductal carcinoma in situ of the breast (JCOG1505, LORETTA trial)
Scientific Title Single-arm confirmatory trial of endocrine therapy alone for estrogen receptor-positive, low-risk ductal carcinoma in situ of the breast (JCOG1505, LORETTA trial)
Scientific Title:Acronym Single-arm confirmatory trial of endocrine therapy alone for estrogen receptor-positive, low-risk ductal carcinoma in situ of the breast (JCOG1505, LORETTA trial)
Region
Japan

Condition
Condition Low-risk ductal carcinoma in situ (DCIS) of the breast
Classification by specialty
Breast surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To confirm whether endocrine therapy alone for estrogen receptor-positive low-risk DCIS is safe and effective compared with the current standard treatment.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2
Developmental phase Phase III

Assessment
Primary outcomes 5-year cumulative incidence of invasive-ipsilateral breast tumor (I-IBT)
Key secondary outcomes 5-year cumulative incidence of I-IBT >1.0 cm, I-IBT-free survival, Overall survival, Breast cancer specific survival, Contralateral invasive breast cancer free survival, Proportion of ipsilateral surgery, Time to surgery for ipsilateral breast cancer, Time-to-treatment-failure , Adverse events, Serious adverse events

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 A: Tamoxifen 20 mg daily for 5 years
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit
75 years-old >=
Gender Female
Key inclusion criteria 1. All of the following conditions are fulfilled by biopsy (core needle biopsy or vacuum-assisted biopsy) from the breast primary site within 84 days before the registration:
i) Histologically proven DCIS,
ii) Must be classified as low (NG1) or intermediate (NG2) nuclear grade,
iii) No comedo necrosis,
iv) High estrogen receptor positive is defined in immunohistochemical staining,
v) HER2-negative
2. All of the following conditions are fulfilled by examination within 84 days before the registration:
i) No palpable mass,
ii) The presence of calcification in MMG,
iii) No mammographic mass,
iv) No invasive cancer findings in US and MRI,
v) The tumor diameters measured by MMG, US and MRI are all 2.5 cm or less,
vi) No multiple lesions in either ipsilateral breast or contralateral breast,
vii) No regional lymph node metastasis in MMG, US and MRI,
viii) No distant metastasis in image examination or clinical findings
3. ECOG performance status (PS) of 0 or 1
4. No history of both non-invasive and invasive breast cancer
5. BRCA positivity has not been confirmed (BRCA test is not mandatory)
6. Sufficient organ functions:
i) WBC >= 2,000/mm3
ii) ANC >= 1,000/mm3
iii) Hemoglobin >= 8.0 g/dL
iv) Platelet >= 50,000/mm3
v) AST =< 100 U/L
vi) ALT =< 100 U/L
vii) T.Bil =< 1.5 mg/dL
viii) Creatinine =< 1.5 mg/dL
7. Written informed consent
Key exclusion criteria 1. Simultaneous or metachronous (within 5 years) double cancers
2. Infectious disease with systemic therapy indicated
3. Body temperature of 38 or more degrees Celsius
4. Pregnancy, possible pregnancy, within 28 days after delivery or breast-feeding
5. Psychiatric diseases
6. Continuous systemic steroid or immune-suppressive drug therapy
7. Poorly controlled diabetes mellitus in spite of continuous use of insulin
8. Poorly controlled hypertension
9. Unstable angina pectoris, or history of myocardial infarction within six months
10. Interstitial pneumonitis, pulmonary fibrosis or severe pulmonary emphysema
11. History of uterine cancer
12. History of thrombosis, embolism
Target sample size 340

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Hiroji Iwata
Organization Aichi Cancer Center Hospital
Division name Department of Breast Oncology
Zip code
Address 1-1, Kanokoden, Chikusa-ku, Nagoya City, Aichi, 464-8661, Japan
TEL 052-762-6111
Email hiwata@aichi-cc.jp

Public contact
Name of contact person
1st name
Middle name
Last name Chizuo Kanbayashi
Organization JCOG1505 Coordinating Office
Division name Department of Breast Oncology, Niigata Cancer Center Hospital
Zip code
Address 2-15-3, Kawagishicho, Chuo-ku, Niigata City, Niigata, 951-8566, Japan
TEL 025-266-5111
Homepage URL http://www.jcog.jp/
Email JCOG_sir@ml.jcog.jp

Sponsor
Institute Japan Clinical Oncology Group (JCOG)
Institute
Department

Funding Source
Organization National Cancer Center
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 国立病院機構北海道がんセンター(北海道)
岩手医科大学(岩手県)
東北大学病院(宮城県)
筑波大学医学医療系(茨城県)
自治医科大学(栃木県)
群馬県立がんセンター(群馬県)
埼玉県立がんセンター(埼玉県)
国立がん研究センター東病院(千葉県)
千葉県がんセンター(千葉県)
国立がん研究センター中央病院(東京都)
がん・感染症センター都立駒込病院(東京都)
国立病院機構東京医療センター(東京都)
昭和大学病院(東京都)
がん研究会有明病院(東京都)
虎の門病院(東京都)
聖路加国際病院(東京都)
東海大学医学部(神奈川県)
聖マリアンナ医科大学(神奈川県)
北里大学医学部(神奈川県)
新潟県立がんセンター新潟病院(新潟県)
静岡県立総合病院(静岡県)
静岡県立静岡がんセンター(静岡県)
愛知県がんセンター中央病院(愛知県)
国立病院機構名古屋医療センター(愛知県)
名古屋市立大学病院(愛知県)
近畿大学医学部(大阪府)
大阪国際がんセンター(大阪府)
国立病院機構大阪医療センター(大阪府)
岡山大学病院(岡山県)
国立病院機構呉医療センター・中国がんセンター(広島県)
広島大学病院(広島県)
広島市立広島市民病院(広島県)
国立病院機構福山医療センター(広島県)
広島市立安佐市民病院(広島県)
国立病院機構四国がんセンター(愛媛県)
国立病院機構九州がんセンター(福岡県)
北九州市立医療センター(福岡県)
国立病院機構長崎医療センター(長崎県)
熊本大学医学部(熊本県)
博愛会相良病院(鹿児島県)

Other administrative information
Date of disclosure of the study information
2017 Year 07 Month 20 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2017 Year 04 Month 18 Day
Date of IRB
Anticipated trial start date
2017 Year 07 Month 20 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Last follow-up date 2033/1/20

Management information
Registered date
2017 Year 07 Month 20 Day
Last modified on
2017 Year 07 Month 20 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032260

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.